Results 31 to 40 of about 229,168 (314)
Major Outcomes in Atrial Fibrillation Patients with One Risk Factor: Impact of Time in Therapeutic Range [PDF]
, 2016 BACKGROUND: The benefits and harms of oral anticoagulation (OAC) therapy in patients with only one stroke risk factor (i.e. CHA2DS2-VASc= 1 in males, or 2 in females) has been subject of debate.
Lip, Gregory Y. H., Proietti, Marco
core +2 more sources
No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke [PDF]
, 2012 Background: Dabigatran etexilate (DE) is a new oral direct thrombin inhibitor. Clinical trials point towards a favourable risk-to-benefit profile of DE compared to warfarin. In this study, we evaluated whether hemorrhagic transformation (HT) occurs after
Bohmann, Ferdinand +6 more
core +3 more sources
Time-trends and treatment gaps in the antithrombotic management of patients with atrial fibrillation after percutaneous coronary intervention: Insights from the CHUM AF-STENT Registry. [PDF]
, 2020 BACKGROUND: The management of atrial fibrillation and flutter (AF) patients undergoing percutaneous coronary intervention (PCI) has undergone a rapid recent evolution. In 2016, the Canadian Cardiovascular Society (CCS) published expert recommendations to
Boivin-Proulx, L-A +7 more
core +1 more source
Management considerations of massive hemoptysis while on extracorporeal membrane oxygenation. [PDF]
, 2016 BACKGROUND: Veno-arterial extracorporeal membrane oxygenation (V-A ECMO) is a life-saving procedure in patients with both respiratory and cardiac failure. Bleeding complications are common since patients must be maintained on anticoagulation.
Cavarocchi, Nicholas C. +5 more
core +2 more sources
Hematology, 2001 Abstract Despite refinements and standardization in the use of anticoagulants, many problems remain for clinicians. Dr. Crowther describes appropriate starting and maintenance doses of warfarin, factors accounting for inter- and intra-observer variability and importantly, the management of the over-anticoagulated patients and bleeding ...
J A, Ginsberg +3 more
openaire +2 more sources
Deutsches Ärzteblatt international, 2018 Much new evidence on oral anticoagulation has come to light in recent years. Non-vitamin-K-dependent oral anti- coagulants (NOAC) have been developed and have been introduced into clinical practice. In this review, we present the current state of the evidence on anticoagulation for various indications with vitamin K antagonists (VKA) and with NOAC.This
Ertunc, Altiok, Nikolaus, Marx
openaire +2 more sources
Anticoagulants for acute ischaemic stroke [PDF]
, 2015 Peer reviewedPublisher ...
Counsell, Carl +2 more
core +1 more source
Research and Practice in Thrombosis and HaemostasisBackground: The international normalized ratio (INR) is designed to monitor vitamin K antagonist (VKA) treatment. Before patients start a self-managing VKA program, parallel measurements are conducted to compare point-of-care testing (POCT) INR with ...
Nikolaj Julian Skrøder Nytofte +1 more
doaj +1 more source
Secondary thrombosis prevention practice patterns in pediatrics: Results of an international survey
Research and Practice in Thrombosis and Haemostasis, 2022 Background Pediatric venous thromboembolism (VTE) rates continue to increase. Although most children present with transient provoking factors, some have persistent prothrombotic risks beyond the initial treatment period warranting secondary ...
Hope P. Wilson +4 more
doaj +1 more source
Frontiers in Pharmacology, 2023 Background: The benefits and risks of starting anticoagulation therapy, such as direct oral anticoagulations (DOACs) or warfarin, in atrial fibrillation (AF) patients with a history of intracranial hemorrhage (ICH) remain controversial.
Qiang Zhou +6 more
doaj +1 more source